You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

monoclonal anti-PD-1 immunotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)

Not yet recruiting
  • Colon Neoplasm
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Pegylated Liposomal Doxorubicin, Doxorubicin, Anti-PD-1 mAb)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Pegylated Liposomal Doxorubicin
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 15, 2023

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

Melanoma Trial (pembrolizumab, )

Active, not recruiting
Has Results
  • Melanoma
  • pembrolizumab
  • placebo
  • (no location specified)
Aug 18, 2022

Melanoma Trial in Moscow (Anti-PD-1 mAb)

Recruiting
  • Melanoma
  • Anti-PD-1 monoclonal antibody
  • Moscow, Russian Federation
    N.N. Blokhin Russian Cancer Research Center, Kashirskoye shosse
Jun 13, 2021

Advanced Cancer Trial in Worldwide (Relatlimab, Nivolumab, BMS-986205)

Recruiting
  • Advanced Cancer
  • Relatlimab
  • +3 more
  • Duarte, California
  • +23 more
Oct 24, 2022

Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Oligometastatic Disease
  • PD-1 combined with SBRT
  • Guangzhou, Guangdong, China
    Mian Xi
Dec 18, 2022

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)

Enrolling by invitation
  • Malignant Melanomas
  • Recombinant Human Adenovirus Type 5 Injection
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital, Department of Internal Medicine, Ward 19
Jul 7, 2023

Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston (biological,

Recruiting
  • Advanced Bladder Carcinoma
  • +34 more
  • Atezolizumab
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Immunotherapy, Analgesia, NSCLC Trial in Tianjin (neoadjuvant immunotherapy, Neoadjuvant chemo)

Recruiting
  • Immunotherapy
  • +3 more
  • neoadjuvant immunotherapy
  • Neoadjuvant chemotherapy
  • Tianjin, Tianjin, China
  • +2 more
Aug 23, 2022

Advanced Rectal Cancer, Distal Metastasis Trial in Shanghai (a combination therapy)

Not yet recruiting
  • Advanced Rectal Cancer
  • Distal Metastasis
  • a combination therapy including tislelizumab
  • Shanghai, Shanghai, China
    Xinxiang Li
Nov 12, 2022

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis Trial in Shanghai (a combination therapy)

Not yet recruiting
  • Advanced Rectal Cancer
  • +3 more
  • a combination therapy including tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 9, 2022

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Lung Cancer Trial in Madrid (Microbiota Transplant plus anti PD1 therapy, anti PD1 therapy)

Recruiting
  • Lung Cancer
  • Microbiota Transplant plus anti PD1 therapy
  • anti PD1 therapy
  • Madrid, Spain
    Hospital Universitario Ramón y Cajal
Oct 3, 2022

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Immunotherapy in Upper Tract Urothelial Carcinoma

Not yet recruiting
  • Urothelial Carcinoma
  • Evaluation of anti-PD-(L)1 immunotherapy efficacy
  • (no location specified)
Oct 27, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Liver, Metastatic Malignant Tumor in the Lung Trial in Houston

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Hafnium Oxide-containing Nanoparticles NBTXR3
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

    Not yet recruiting
    • Cervical Cancer
    • Anti-PD-1 antibody balstilimab
    • Amsterdam, Netherlands
      Amsterdam UMC
    Oct 17, 2023

    Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

    Recruiting
    • Locally Advanced Bladder Urothelial Carcinoma
    • +18 more
    • Los Angeles, California
    • +2 more
    Jun 28, 2022